254 related articles for article (PubMed ID: 37833748)
1. Customizing cancer treatment at the nanoscale: a focus on anaplastic thyroid cancer therapy.
Wang J; Tan J; Wu B; Wu R; Han Y; Wang C; Gao Z; Jiang D; Xia X
J Nanobiotechnology; 2023 Oct; 21(1):374. PubMed ID: 37833748
[TBL] [Abstract][Full Text] [Related]
2. Capsaicin restores sodium iodine symporter-mediated radioiodine uptake through bypassing canonical TSH‒TSHR pathway in anaplastic thyroid carcinoma cells.
Xu S; Cheng X; Wu J; Wang Y; Wang X; Wu L; Yu H; Bao J; Zhang L
J Mol Cell Biol; 2022 Jan; 13(11):791-807. PubMed ID: 34751390
[TBL] [Abstract][Full Text] [Related]
3. Advances in targeted therapy for anaplastic thyroid carcinoma.
Qian C; Jiang L; Xu S; Wang J; Tan Z; Xin Y; Ge M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):685-693. PubMed ID: 35347921
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways.
Samimi H; Fallah P; Naderi Sohi A; Tavakoli R; Naderi M; Soleimani M; Larijani B; Haghpanah V
Acta Med Iran; 2017 Mar; 55(3):200-208. PubMed ID: 28282720
[TBL] [Abstract][Full Text] [Related]
5. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
7. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
8. Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Nakayama H; Saito N; Kasajima R; Suganuma N; Rino Y; Masudo K; Yamazaki H; Toda S; Sekihara K; Iwasaki H; Hoshino D
Anticancer Res; 2023 Mar; 43(3):1073-1077. PubMed ID: 36854530
[TBL] [Abstract][Full Text] [Related]
9. MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer.
ElMokh O; Taelman V; Radojewski P; Roelli MA; Stoss A; Dumont RA; Dettmer MS; Phillips WA; Walter MA; Charles RP
J Nucl Med; 2019 Jul; 60(7):917-923. PubMed ID: 30464041
[TBL] [Abstract][Full Text] [Related]
10. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
11. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy.
Jungels C; Pita JM; Costante G
Curr Opin Oncol; 2023 Jan; 35(1):1-9. PubMed ID: 36398690
[TBL] [Abstract][Full Text] [Related]
13. [Anaplastic thyroid carcinoma : new therapeutic approaches].
Stamatiou A; Herrera-Gómez RG; Szturz P; Bisig B; Romano E; Sykiotis G; Gorostidi F; La Rosa S; Kopp P; Cristina V
Rev Med Suisse; 2021 May; 17(739):962-966. PubMed ID: 34009754
[TBL] [Abstract][Full Text] [Related]
14. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
15. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study.
Hanna GJ; Busaidy NL; Chau NG; Wirth LJ; Barletta JA; Calles A; Haddad RI; Kraft S; Cabanillas ME; Rabinowits G; O'Neill A; Limaye SA; Alexander EK; Moore FD; Misiwkeiwicz K; Thomas T; Nehs M; Marqusee E; Lee SL; Jänne PA; Lorch JH
Clin Cancer Res; 2018 Apr; 24(7):1546-1553. PubMed ID: 29301825
[No Abstract] [Full Text] [Related]
16. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma.
Yang S; Ji D; Xue F; Chen T; Wang Y; Ji Q
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1770. PubMed ID: 36535914
[TBL] [Abstract][Full Text] [Related]
17. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
18. [Personalized approach to anaplastic thyroid carcinoma].
Wächter S; Bartsch DK; Maurer E
Chirurgie (Heidelb); 2024 Mar; 95(3):192-199. PubMed ID: 37973622
[TBL] [Abstract][Full Text] [Related]
19. Preclinical and clinical combination therapies in the treatment of anaplastic thyroid cancer.
Gentile D; Orlandi P; Banchi M; Bocci G
Med Oncol; 2020 Feb; 37(3):19. PubMed ID: 32108281
[TBL] [Abstract][Full Text] [Related]
20. Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer.
Li W; Li Y; Li J; Pang H
Technol Cancer Res Treat; 2023; 22():15330338231169870. PubMed ID: 37122242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
